This report was first published by Endpoints News. To see the original version, click here
It’s possible to imagine a world in which Novo Nordisk remained a medium-to-large European pharma company, a little like Merck KGaA or Boehringer Ingelheim, ticking over for hundreds of years, quietly changing patients’ lives without being part of a once-in-a-generation breakthrough.
But Novo’s scientists invented semaglutide, and that possibility vanished forever.
您已阅读5%（456字），剩余95%（8720字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。